Immunovant Inc
NASDAQ:IMVT
Intrinsic Value
Immunovant, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IMVT.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Immunovant Inc's business.
What risks and challenges
does Immunovant Inc face in the near future?
Summarize the latest earnings report
of Immunovant Inc.
Provide P/E
for Immunovant Inc and its competitors.
Balance Sheet Decomposition
Immunovant Inc
Current Assets | 710.8m |
Cash & Short-Term Investments | 690.9m |
Receivables | 1m |
Other Current Assets | 18.8m |
Non-Current Assets | 670k |
PP&E | 670k |
Current Liabilities | 32.1m |
Accounts Payable | 3.9m |
Accrued Liabilities | 28.2m |
Earnings Waterfall
Immunovant Inc
Revenue
|
0
USD
|
Operating Expenses
|
-253.6m
USD
|
Operating Income
|
-253.6m
USD
|
Other Expenses
|
10.1m
USD
|
Net Income
|
-243.4m
USD
|
Free Cash Flow Analysis
Immunovant Inc
What is Free Cash Flow?
IMVT Profitability Score
Profitability Due Diligence
Immunovant Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Immunovant Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
IMVT Solvency Score
Solvency Due Diligence
Immunovant Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Immunovant Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMVT Price Targets Summary
Immunovant Inc
According to Wall Street analysts, the average 1-year price target for IMVT is 51.73 USD with a low forecast of 40.4 USD and a high forecast of 59.85 USD.
Ownership
IMVT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IMVT Price
Immunovant Inc
Average Annual Return | 70.22% |
Standard Deviation of Annual Returns | 114.64% |
Max Drawdown | -94% |
Market Capitalization | 4.7B USD |
Shares Outstanding | 145 292 992 |
Percentage of Shares Shorted | 12.42% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 68 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. The firm is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn). The company is also developing IMVT-1401 as a fixed-dose subcutaneous injection and focused initial development on the treatment of myasthenia gravis (MG), warm autoimmune hemolytic anemia (WAIHA), and thyroid eye disease (TED).